Last reviewed · How we verify
Standard dose of TNFi
TNF inhibitors block tumor necrosis factor (TNF), a key inflammatory cytokine that drives immune-mediated inflammation.
TNF inhibitors block tumor necrosis factor (TNF), a key inflammatory cytokine that drives immune-mediated inflammation. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.
At a glance
| Generic name | Standard dose of TNFi |
|---|---|
| Also known as | etanercept 50 mg every 7 days, adalimumab 40 mg every 2 weeks, certolizumab pegol 200 mg every 2 weeks, golimumab 50 mg every 4 weeks, infliximab 5 mg/kg every 6 weeks |
| Sponsor | University Health Network, Toronto |
| Drug class | TNF inhibitor |
| Target | TNF-α (tumor necrosis factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
TNF is a central pro-inflammatory cytokine produced by macrophages and other immune cells. By neutralizing TNF through monoclonal antibodies, receptor fusion proteins, or small molecules, TNFi reduce downstream inflammatory signaling and immune cell activation. This suppresses the pathologic inflammation characteristic of autoimmune and inflammatory diseases.
Approved indications
- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Crohn's disease
- Ulcerative colitis
- Psoriasis
- Juvenile idiopathic arthritis
Common side effects
- Increased infection risk (including tuberculosis, opportunistic infections)
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Malignancy (lymphoma, solid tumors)
- Demyelinating disease
- Heart failure exacerbation
Key clinical trials
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM) (PHASE4)
- Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade (PHASE3)
- Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (NA)
- Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard dose of TNFi CI brief — competitive landscape report
- Standard dose of TNFi updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI